venlafaxine hydrochloride has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atasoy, A; Daglioglu, N; Gören, İE; Yavuz-Guzel, E | 1 |
| Delgado, CP; Nogara, PA; Omage, FB; Teixeira Rocha, JB; Tronco Pauletto, PJ | 1 |
| Du, X; Gong, H; Lei, M; Tan, Q; Wei, J; Wu, L; Zhao, L; Zhao, R | 1 |
3 other study(ies) available for venlafaxine hydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Impact of COVID- 19 pandemic on antidepressants consumptions by wastewater analysis in Turkey.
Topics: Antidepressive Agents; Chromatography, Liquid; COVID-19; Humans; Pandemics; Tandem Mass Spectrometry; Turkey; Venlafaxine Hydrochloride; Wastewater | 2022 |
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; COVID-19; Fluoxetine; Humans; Molecular Docking Simulation; Papain; Peptide Hydrolases; Protease Inhibitors; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2023 |
Discontinuation Syndrome of Extended-Release Venlafaxine during the COVID-19 Epidemic.
Topics: Antidepressive Agents, Second-Generation; COVID-19; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Epidemics; Humans; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |